ARTICLE | Clinical News
MTC-DOX: Phase I/II
November 25, 2002 8:00 AM UTC
FeRx started a U.S. and European Phase I/II repeat dosing study of MTC-DOX in 20 metastatic liver cancer patients. ...
Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
FeRx started a U.S. and European Phase I/II repeat dosing study of MTC-DOX in 20 metastatic liver cancer patients. ...